1. All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.

* Correspondence: kneena1980@gmail.com

Keywords: gut microbiome, metabolome, impaired glucose control, type 2 diabetes

1. INTRODUCTION

The human gut microbiome—a complex and dynamic community of trillions of microbes—has emerged as a key regulator of metabolic health. Its influence extends beyond nutrient digestion and immune modulation to impact host metabolism, including glucose homeostasis [1]. Simultaneously, the metabolome, encompassing all small molecules produced by both host and microbes, offers a functional readout of physiological and pathological processes. The interconnection between these two systems has been termed the microbiome-metabolome axis [2]. Disruptions in this axis are increasingly implicated insulin resistance, chronic inflammation, and impaired glucose regulation. Understanding these dynamics not only sheds light on disease mechanisms but also opens avenues for microbiome-informed interventions.

2. Microbiome–Metabolome Interactions in Glucose Regulation

The gut microbiota contributes to glucose control via the production of short-chain fatty acids (SCFAs), bile acid metabolism, modulation of gut permeability, and interaction with immune signaling pathways. SCFAs such as acetate, propionate, and butyrate, produced through bacterial fermentation of dietary fibers, are key regulators of intestinal health, gluconeogenesis, and insulin sensitivity [3]. Butyrate-producing bacteria like Faecali bacterium prausnitzii and Roseburia spp. have been consistently associated with better glycemic control. On the other hand, a rise in opportunistic pathogens and decreased microbial diversity has been linked to low-grade systemic inflammation and insulin resistance [4].

3. Gut Microbiota and Metabolic Health

The composition and functional capacity of the gut microbiome differ markedly between healthy individuals and those with impaired glucose tolerance or type 2 diabetes [5]. Studies have shown that individuals with diabetes tend to exhibit reduced microbial gene richness and lower abundance of SCFA-producing bacteria. An overrepresentation of Bacteroides, Prevotella, and Ruminococcus gnavus, as well as increased branched-chain amino acid (BCAA) metabolism, has been associated with adverse metabolic profiles [6]. Animal studies further confirm that transplantation of microbiota from insulin-resistant individuals can transmit glucose intolerance to germ-free mice, highlighting the causal role of the microbiome [7].

4. Key Microbial Metabolites in Glucose Homeostasis

Beyond SCFAs, other microbial metabolites such as indole derivatives, secondary bile acids, trimethylamine N-oxide (TMAO), and phenolic compounds have emerged as important regulators of host metabolism [8]. For instance, indole propionic acid, derived from tryptophan metabolism, has shown protective effects against type 2 diabetes by improving insulin secretion. Conversely, elevated levels of TMAO have been linked to atherosclerosis and insulin resistance. These metabolites influence host signaling pathways such as GLP-1 secretion, inflammation, and mitochondrial function, making them potential therapeutic targets [9].

5. Microbiome–Metabolome Alterations in Impaired Glucose Control

Metabolomic profiling of individuals with prediabetes and diabetes reveals distinct signatures, including altered levels of SCFAs, amino acids, bile acids, and lipid derivatives. These changes are not only markers of disease but also active participants in disease progression [10]. For example, elevated levels of isobutyrate and isovalerate, derived from protein fermentation, have been associated with insulin resistance. Similarly, decreased concentrations of protective SCFAs in feces and serum are consistently reported in individuals with poor glucose control [11]. Such alterations suggest a shift in microbial metabolic capacity that can impact host energy metabolism, inflammatory responses, and hormonal regulation.

6. Lifestyle Interventions and Their Effects on the Microbiome and Metabolome

Diet and physical activity are cornerstones of metabolic health and known modulators of the gut microbiome [12]. Dietary interventions, particularly those high in fiber and plant-based foods, promote microbial diversity and enhance SCFA production. For example, adherence to a Mediterranean diet has been linked to increases in Bifidobacterium and Akkermansia muciniphila, along with favorable changes in lipid and glucose metabolism [13]. Exercise has also been shown to increase microbial diversity and improve the abundance of SCFA-producing bacteria, independently of diet. These lifestyle-induced microbiome shifts are accompanied by beneficial metabolomic changes, including reductions in inflammatory markers and improved insulin sensitivity [14].

7. Interindividual Variability in Response to Lifestyle Changes

Not all individuals respond equally to lifestyle interventions, and emerging evidence suggests that the baseline microbiome and metabolome profiles can predict responsiveness [15]. Personalized nutrition trials have demonstrated that microbiome composition can forecast glycemic responses to specific meals. Individuals with higher levels of fiber-degrading microbes, for instance, tend to experience greater improvements in glucose control following dietary changes [16]. Metabolomic signatures, such as baseline SCFA levels or amino acid profiles, also influence intervention outcomes. These findings underscore the need for precision medicine approaches that incorporate microbiome and metabolome data to tailor lifestyle recommendations [17].

8. Clinical and Preclinical Evidence

Clinical trials and observational studies have consistently supported the role of microbiome-metabolome interactions in metabolic regulation. In one study, a high-fiber diet improved HbA1c levels in type 2 diabetes patients while selectively enriching butyrate-producing bacteria [18]. Another randomized controlled trial found that fecal microbiota transplantation (FMT) from lean donors temporarily improved insulin sensitivity in obese recipients, although effects diminished over time. Preclinical models reinforce these findings, with germ-free or antibiotic-treated mice displaying altered glucose metabolism and hormone secretion [19]. Moreover, interventions targeting microbial metabolites—such as prebiotics, probiotics, and postbiotics—have shown promise in improving metabolic outcomes, though more large-scale trials are needed.

9. Limitations and Future Directions

Despite promising findings, several challenges remain. Most studies are correlative, and establishing causality between microbial changes and metabolic outcomes requires controlled interventions. Interindividual variability, influenced by genetics, diet, environment, and medication use, complicates interpretation. Additionally, standardization in microbiome and metabolome measurement techniques is lacking, making comparisons across studies difficult. Future research should focus on longitudinal studies, mechanistic trials, and multi-omics integration to unravel the complex interactions within the microbiome-metabolome-host axis. Personalized therapeutic strategies, including diet, microbiota-targeted drugs, and metabolic modulators, hold great potential for preventing and managing impaired glucose control.

10. CONCLUSION

The dynamic interplay between the gut microbiome and metabolome significantly influences glucose metabolism and the pathogenesis of insulin resistance and type 2 diabetes. Lifestyle interventions, particularly diet and exercise, modulate this axis in beneficial ways, though individual responses vary based on baseline microbial and metabolic profiles. Understanding these relationships provides a promising avenue for personalized nutrition and microbiota-targeted therapies aimed at improving glucose control. Continued research integrating microbiome, metabolome, and clinical data will be essential for translating these insights into effective and individualized treatments.

REFERENCES

1. Canfora, E. E., Meex, R. C. R., Venema, K., & Blaak, E. E. (2019). Gut microbial metabolites in obesity, NAFLD and T2DM. Nature Reviews Endocrinology, 15(5), 261–273.
2. De Filippis, F., Pellegrini, N., Vannini, L., Jeffery, I. B., La Storia, A., Laghi, L., … & Ercolini, D. (2016). High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut, 65(11), 1812–1821.
3. Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., … & Raes, J. (2016). Population-level analysis of gut microbiome variation. Science, 352(6285), 560–564.
4. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., … & Ehrlich, S. D. (2013). Richness of human gut microbiome correlates with metabolic markers. Nature, 500(7464), 541–546.
5. Sonnenburg, J. L., & Bäckhed, F. (2016). Diet-microbiota interactions as moderators of human metabolism. Nature, 535(7610), 56–64.
6. Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., … & Segal, E. (2015). Personalized nutrition by prediction of glycemic responses. Cell, 163(5), 1079–1094.
7. Kootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., … & Nieuwdorp, M. (2017). Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metabolism, 26(4), 611–619.
8. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., … & Wang, J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 55–60.
9. Nicholson, J. K., Holmes, E., Kinross, J. M., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012). Host-gut microbiota metabolic interactions. Science, 336(6086), 1262–1267.
10. Wu, H., Lv, B., Zhi, L., Shao, Y., Liu, X., Mitteregger, M., … & Bäckhed, F. (2025). Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nature Medicine, 1-10.
11. Wu, H., Guzior, D. V., Martin, C., Neugebauer, K. A., Rzepka, M. M., Lumeng, J. C., … & de Los Campos, G. (2024). Longitudinal analyses of infants’ microbiome and metabolome reveal microbes and metabolites with seemingly coordinated dynamics. Communications Biology, 7(1), 1506.
12. Sang, X., Li, S., Guo, R., Yan, Q., Liu, C., Zhang, Y., … & Sun, W. (2023). Dynamics and ecological reassembly of the human gut microbiome and the host metabolome in response to prolonged fasting. Frontiers in Microbiology, 14, 1265425.
13. Zhang, B., Zhang, X., Luo, Z., Ren, J., Yu, X., Zhao, H., … & Zhao, L. (2024). Microbiome and metabolome dysbiosis analysis in impaired glucose tolerance for the prediction of progression to diabetes mellitus. Journal of Genetics and Genomics, 51(1), 75-86.
14. Zhou, W., Sailani, M. R., Contrepois, K., Zhou, Y., Ahadi, S., Leopold, S. R., … & Snyder, M. (2019). Longitudinal multi-omics of host–microbe dynamics in prediabetes. Nature, 569(7758), 663-671.
15. Al Bataineh, M. T., Künstner, A., Dash, N. R., Alsafar, H. S., Ragab, M., Schmelter, F., … & Ibrahim, S. M. (2023). Uncovering the relationship between gut microbial dysbiosis, metabolomics, and dietary intake in type 2 diabetes mellitus and in healthy volunteers: a multi-omics analysis. Scientific reports, 13(1), 17943.
16. Shilo, S., Godneva, A., Rachmiel, M., Korem, T., Bussi, Y., Kolobkov, D., … & Segal, E. (2022). The gut microbiome of adults with type 1 diabetes and its association with the host glycemic control. Diabetes Care, 45(3), 555-563.
17. Yue, T., Tan, H., Wang, C., Liu, Z., Yang, D., Ding, Y., … & Luo, S. (2022). High-risk genotypes for type 1 diabetes are associated with the imbalance of gut microbiome and serum metabolites. Frontiers in Immunology, 13, 1033393.
18. Kashani, A., Brejnrod, A. D., Jin, C., Kern, T., Madsen, A. N., Holm, L. A., … & Arumugam, M. (2019). Impaired glucose metabolism and altered gut microbiome despite calorie restriction of ob/ob mice. Animal microbiome, 1(1), 11.
19. Morsy, Y., Shafie, N. S., & Amer, M. (2025). Integrative analysis of gut microbiota and metabolic pathways reveals key microbial and metabolomic alterations in diabetes. Scientific Reports, 15(1), 30686.